A Multicenter Randomized Controlled Trial comparing [18F]PSMA-1007-PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer (Vinder af posterprisen)

PRISMA-PET

Buch-Olsen, Karen M; Vilstrup, Mie Holm; Hansen, Steinbjørn; Hess, Søren; Holdgaard, Paw Christian; Poulsen, Mads Hvid; Dam, Johan Hygum; Sørensen Madsen, Søren; Hildebrandt, Malene Grubbe

Publication date:
2021

Document version:
Final published version

Citation for pulished version (APA):
Buch-Olsen, K. M., Vilstrup, M. H., Hansen, S., Hess, S., Holdgaard, P. C., Poulsen, M. H., Dam, J. H., Sørensen Madsen, S., & Hildebrandt, M. G. (2021). *A Multicenter Randomized Controlled Trial comparing [18F]PSMA-1007-PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer (Vinder af posterprisen): PRISMA-PET*. Abstract from Dansk Selskab for Klinisk Fysiologi og Nuklearmedicins Årsmøde 2021, Aalborg, Denmark.

A Multicenter Randomized Controlled Trial comparing [^{18}F]PSMA-1007-PET/CT with Conventional Imaging in Primary Staging of Prostate Cancer.

Authors: K. M. Buch-Olsen, M. H. Vilstrup, S. Hansen, S. Hess, P. C. Holdgaard,
M. H. Poulsen, J. H. Dam, S. S. Madsen, M. G. Hildebrandt.
Departments of Nuclear Medicine, Urology and Oncology in Region of Southern Denmark.

Aim

This study aims to evaluate the impact on treatment strategy, progression-free survival and quality of life of staging primary Prostate Cancer patients with PSMA-PET/CT.

EudraCT number 2021-000123-12



Inclusion criteria

- Biopsy verified prostate cancer

AND

- PSA ≥ 20 ng/ml **OR**
- Gleason Score ≥ 4+3 **OR**
- Tumor stage cT2c or above **OR**
- Staging by imaging warranted due to suspicion of metastases

Primary endpoints (A vs. B)

- Choice of Treatment
- Progression free survival
- Quality of life

Secondary endpoints:

- Overall survival (A vs. B)
- Accuracy (NaF vs. PSMA, bone)

Soon visible on clinicaltrials.gov



The PSMA-PET/CT shows marked uptake in this 6 mm lymph node, suspicious for a metastasis.



Patient recruitment from all centers in the Region of Southern Denmark

kmbo@rsyd.dk – Nothing to disclose

Nuclear Medicine
Odense University Hospital Denmark

SDU